Israeli device maker Premia Spine confirmed today that it had raised $7 million, planning on using part of the funds to pursue FDA approval for its spinal fixation devices.
CEO Ron Sacher told MassDevice.com today that the reports about the company’s latest fundraising efforts are true, and that Premia is looking to raise another $3 million to close out the financing round.
Cancer diagnostics firm Neoprobe Corp. (NYSE:NEOP) sold its Gamma Detection Systems sector to Devicor Medical Products Inc. in a deal that’s worth up to $50 million.
Devicor, based in Pleasant Valley, Wis., agreed to pay $30 million up front and up to $20 million in royalty payments.
Dublin, Ohio-based Neoprobe will get the full royalty payment if Devicor tops $21 million in sales of the devices in the next five years.